- Home
- SPRO vs IGA Comparison
SPRO vs IGA Comparison
Compare SPRO & IGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRO
- IGA
- Stock Information
- Founded
- SPRO 2013
- IGA 2005
- Country
- SPRO United States
- IGA United States
- Employees
- SPRO N/A
- IGA N/A
- Industry
- SPRO Biotechnology: Pharmaceutical Preparations
- IGA Investment Managers
- Sector
- SPRO Health Care
- IGA Finance
- Exchange
- SPRO Nasdaq
- IGA Nasdaq
- Market Cap
- SPRO 162.1M
- IGA 151.0M
- IPO Year
- SPRO 2017
- IGA N/A
- Fundamental
- Price
- SPRO $2.20
- IGA $9.69
- Analyst Decision
- SPRO Buy
- IGA
- Analyst Count
- SPRO 4
- IGA 0
- Target Price
- SPRO $5.00
- IGA N/A
- AVG Volume (30 Days)
- SPRO 789.2K
- IGA 42.3K
- Earning Date
- SPRO 08-04-2025
- IGA 01-01-0001
- Dividend Yield
- SPRO N/A
- IGA 8.93%
- EPS Growth
- SPRO N/A
- IGA N/A
- EPS
- SPRO N/A
- IGA N/A
- Revenue
- SPRO $44,584,000.00
- IGA N/A
- Revenue This Year
- SPRO N/A
- IGA N/A
- Revenue Next Year
- SPRO N/A
- IGA N/A
- P/E Ratio
- SPRO N/A
- IGA N/A
- Revenue Growth
- SPRO N/A
- IGA N/A
- 52 Week Low
- SPRO $0.51
- IGA $7.77
- 52 Week High
- SPRO $3.22
- IGA $8.88
- Technical
- Relative Strength Index (RSI)
- SPRO 33.44
- IGA 36.09
- Support Level
- SPRO $2.30
- IGA $9.67
- Resistance Level
- SPRO $2.45
- IGA $9.85
- Average True Range (ATR)
- SPRO 0.12
- IGA 0.09
- MACD
- SPRO -0.07
- IGA -0.00
- Stochastic Oscillator
- SPRO 2.80
- IGA 8.33
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
About IGA Voya Global Advantage and Premium Opportunity Fund of Beneficial Interest
Voya Global Advantage and Premium Opportunity Fund is a United States-based diversified, closed-end management investment company. The fund has two investment objectives. Its primary objective is to provide a high level of income, while the secondary objective is to seek capital appreciation. To achieve these objectives, the fund invests at least 80% of its managed assets in a portfolio of common stocks from various countries around the world, including the United States. Additionally, it uses an integrated derivatives strategy.